去年12月广发基金旗下15只基金跌超8% 10年老将垫底

Core Viewpoint - In December 2025, 15 funds managed by GF Fund experienced a decline of over 8%, with the GF Healthcare Mixed Fund A and C managed by Wu Xingwu leading the losses at -13.3% and -13.27% respectively [1][2]. Fund Performance Summary - The GF Healthcare Mixed Fund A and C have recorded a decline of 41.19% and 42.41% respectively since their inception on October 21, 2020 [1]. - The top ten holdings of the GF Healthcare Mixed Fund include companies such as Kelun-Botai Biotech, Innovent Biologics, and WuXi AppTec [1]. - Other funds managed by Wu Xingwu, including GF Hong Kong-Shenzhen Healthcare Mixed Fund A and C, also reported significant declines in December [2][3]. Additional Fund Details - The GF Healthcare Mixed Fund A had a unit net value of 0.5881 as of January 5, 2026, with a one-month decline of -6.59% and a one-year return of 38.28% [2]. - The GF Healthcare Mixed Fund C had a unit net value of 0.5759 as of January 5, 2026, with a one-month decline of -6.62% and a one-year return of 37.74% [2]. - Other funds with notable declines include the GF Medical Innovation Mixed Fund A and C, which fell by -12.79% and -12.75% respectively [3][4].